SCHEMBL6014150

SCHEMBL6014150

CCC(C)n1ncc(N)c1C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR3 P49019 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.38
ACHE P22303 3/20 0.37
KMO O15229 1/20 0.33
KDM4E B2RXH2 2/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32
GABRB2 P47870 1/20 0.32
GABRA4 P48169 1/20 0.32
GABRE P78334 1/20 0.32
GABRA6 Q16445 1/20 0.32
GABRG1 Q8N1C3 1/20 0.32
GABRG3 Q99928 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20023762 0.83 L3MBTL1 (0.39) HCAR3L3MBTL1ACHEKDM4EALDH1A1
SCHEMBL2373382 0.81 L3MBTL1 (0.41) HCAR3L3MBTL1ACHEKMOKDM4E
SCHEMBL5393771 0.75 L3MBTL1 (0.34) L3MBTL1ACHEKDM4EALDH1A1LMNA
SCHEMBL20874549 0.71 ALDH1A1 (0.41) HCAR3L3MBTL1KDM4EALDH1A1GAA
SCHEMBL26988158 0.70 KMO (0.33) KMOKDM4E
SCHEMBL27137504 0.70 KMO (0.33) KMOKDM4E
SCHEMBL7449090 0.70 KMT2A (0.36) L3MBTL1KDM4EKDM4CALDH1A1LMNA
SCHEMBL15651629 0.69 ADORA2A (0.36) ACHEKDM4EALDH1A1
SCHEMBL14445241 0.69 KMO (0.49) L3MBTL1KMOKDM4EALDH1A1MAPT
SCHEMBL22143750 0.67 L3MBTL1 (0.54) HCAR3L3MBTL1ACHEKDM4EKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060270849-A1 Process for producing pyrimidin-4-one compound UBE INDUSTRIES, LTD. (JP) 2006-11-30 US disclosed
EP-1637523-A1 PROCESS FOR PRODUCING PYRIMIDIN-4-ONE COMPOUND Ube Industries, Ltd. (JP) 2006-03-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270849-A1 Process for producing pyrimidin-4-one compound DDC, ODC1, APRT HCAR3 2932/4885L3MBTL1 4697/4885ACHE 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.